Reducing the mortality gap for people with schizophrenia
Reducing the mortality gap for people with schizophrenia
缩小精神分裂症患者的死亡率差距
批准号：
nhmrc : 1194635
负责人：
金额：
$123.11万
依托单位国家：
澳大利亚
项目类别：
Investigator Grants
财政年份：
2021
资助国家：
澳大利亚
项目状态：
未结题
起止时间：
2021-01-01 至 2025-12-31
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
People with schizophrenia die >16 years earlier than the general population, mostly due to avoidable diseases such as diabetes and heart disease. This research aims to conduct clinical trials among people with schizophrenia of 1. an existing diabetes medication (metformin) to prevent initial weight gain due to antipsychotic medications and 2. a novel diabetes medication (exenatide) to help people who don’t have adequate weight loss with metformin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
